Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
0.4310
Dollar change
+0.0856
Percentage change
24.78
%
Index- P/E- EPS (ttm)-0.72 Insider Own9.67% Shs Outstand57.46M Perf Week26.02%
Market Cap25.42M Forward P/E- EPS next Y-0.56 Insider Trans0.49% Shs Float53.27M Perf Month30.69%
Income-41.72M PEG- EPS next Q-0.15 Inst Own17.26% Short Float / Ratio0.81% / 2.80 Perf Quarter36.70%
Sales0.66M P/S38.51 EPS this Y20.24% Inst Trans-14.47% Short Interest0.43M Perf Half Y34.02%
Book/sh0.63 P/B0.69 EPS next Y16.04% ROA-69.89% Target Price2.17 Perf Year-59.72%
Cash/sh0.68 P/C0.63 EPS next 5Y0.00% ROE-79.05% 52W Range0.26 - 1.33 Perf YTD-56.90%
Dividend- P/FCF- EPS past 5Y41.49% ROI-112.18% 52W High-67.59% Beta1.24
Dividend %- Quick Ratio8.25 Sales past 5Y-0.45% Gross Margin72.08% 52W Low65.13% ATR0.04
Employees30 Current Ratio8.25 Sales Q/Q-53.14% Oper. Margin-6675.72% RSI (14)64.32 Volatility17.32% 11.86%
OptionableYes Debt/Eq0.01 EPS Q/Q18.52% Profit Margin-6330.05% Rel Volume2.61 Prev Close0.35
ShortableYes LT Debt/Eq0.01 EarningsNov 09 AMC Payout- Avg Volume154.90K Price0.43
Recom1.50 SMA2027.22% SMA5033.34% SMA2007.47% Volume405,054 Change24.78%
Date Action Analyst Rating Change Price Target Change
Apr-07-21Initiated Oppenheimer Outperform $14
Feb-23-21Initiated Northland Capital Outperform $21
Nov-11-23 11:06AM
Nov-09-23 04:01PM
Nov-02-23 04:05PM
Oct-26-23 09:00AM
Oct-25-23 09:00AM
04:01PM Loading…
Oct-05-23 04:01PM
Sep-07-23 09:00AM
Aug-10-23 04:01PM
Aug-03-23 04:30PM
04:05PM
Jul-26-23 01:30PM
Jun-30-23 04:30PM
Jun-06-23 04:01PM
May-31-23 05:00PM
May-06-23 08:14AM
04:01PM Loading…
May-04-23 04:01PM
Apr-27-23 05:00PM
Apr-17-23 06:54AM
Apr-13-23 05:00PM
Apr-03-23 04:01PM
Mar-27-23 09:00AM
Mar-11-23 03:14AM
Mar-09-23 04:01PM
Mar-02-23 05:00PM
Mar-01-23 05:00PM
Feb-01-23 05:00PM
Jan-04-23 04:05PM
Jan-03-23 05:00PM
Dec-10-22 03:00PM
Dec-01-22 05:00PM
05:00PM Loading…
Nov-14-22 05:00PM
Nov-03-22 04:01PM
09:05AM
Oct-27-22 05:53PM
Oct-03-22 05:30PM
04:31PM
Sep-27-22 09:00AM
Sep-23-22 09:00AM
Sep-07-22 05:00PM
Aug-09-22 04:05PM
Aug-02-22 05:00PM
Jul-26-22 07:34AM
Jul-14-22 04:01PM
Jun-10-22 04:30PM
09:00AM
Jun-02-22 09:00AM
Jun-01-22 05:00PM
May-26-22 05:15PM
May-17-22 07:40AM
May-05-22 04:01PM
May-02-22 05:00PM
Apr-28-22 05:00PM
03:02PM
Apr-13-22 08:30AM
Apr-01-22 05:00PM
Mar-10-22 04:01PM
Mar-07-22 05:00PM
Mar-01-22 05:00PM
Feb-16-22 10:11AM
Jan-20-22 04:05PM
Jan-19-22 05:38PM
Jan-04-22 04:01PM
Dec-14-21 08:53AM
Dec-13-21 08:00AM
Dec-01-21 05:00PM
Nov-15-21 08:00AM
Nov-09-21 05:00PM
Nov-04-21 04:05PM
Nov-03-21 05:00PM
Nov-02-21 05:00PM
Nov-01-21 04:05PM
Oct-29-21 08:00AM
Oct-27-21 03:03PM
Oct-15-21 10:51AM
Oct-05-21 04:05PM
Oct-01-21 04:01PM
Sep-20-21 08:00AM
08:00AM
Sep-09-21 04:01PM
Sep-01-21 04:01PM
Aug-16-21 01:17PM
Aug-05-21 04:01PM
Aug-02-21 04:05PM
04:04PM
Jul-29-21 03:05PM
08:00AM
Jul-01-21 04:05PM
Jun-01-21 04:05PM
May-31-21 05:02AM
May-26-21 08:00AM
May-19-21 05:30PM
05:01PM
May-17-21 04:01PM
May-06-21 04:01PM
May-03-21 04:01PM
Apr-29-21 04:01PM
Apr-28-21 10:00AM
Apr-20-21 08:24PM
Apr-12-21 04:41PM
07:00AM
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaufmann Gunnar F.Chief Scientific OfficerJun 14Buy0.363,0001,07994,726Jun 14 04:00 PM
Kaufmann Gunnar F.Chief Scientific OfficerJun 12Buy0.3525,0008,74591,726Jun 14 04:00 PM
BREITMEYER JAMES BChief Executive OfficerApr 14Buy0.3050,00014,930196,544Apr 17 06:00 AM
Yazji SalimChief Medical OfficerApr 14Buy0.305,0001,500164,676Apr 14 06:02 PM
BREITMEYER JAMES BChief Executive OfficerApr 13Buy0.29100,00029,000146,544Apr 17 06:00 AM
VINCENT RICHARD GChief Financial OfficerApr 13Buy0.3030,0008,961156,859Apr 14 06:00 AM
Leavitt Chase C.General Counsel/SecretaryApr 13Buy0.2910,0002,900106,901Apr 14 06:00 AM
Yazji SalimChief Medical OfficerApr 13Buy0.2810,0002,850159,676Apr 14 06:02 PM
Leavitt Chase C.General Counsel/SecretaryApr 12Buy0.2915,0004,35096,901Apr 14 06:00 AM
Yazji SalimChief Medical OfficerApr 12Buy0.2810,0002,850149,676Apr 14 06:02 PM